|
- Trialists Grapple with How to Outsmart TREM2 | ALZFORUM
Series - AD PD™ 2025: Advances in Science Therapy: Part 1 of 15: Finally, PET Tracers For α-Synuclein Yield Signal in Idiopathic Parkinson’s Part 2 of 15: New Partnership Forms to Harness AI for Alzheimer’s Research Part 3 of 15: Moving Target: New Biology Casts TREM2 as a Shifty Mark Part 4 of 15: TREM2: A Chill Pill for Neurons? Part 5 of 15: Trialists Grapple with How to Outsmart
- TREM2 - ALZFORUM
TREM2 encodes Triggering Receptor Expressed on Myeloid Cells 2, a transmembrane receptor that modulates microglial activity and survival TREM2 variants cause Nasu-Hakola disease (NHD), a rare autosomal recessive early-onset dementia, and may modify the risk of developing Alzheimer’s disease (AD), frontotemporal dementia (FTD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis
- VG-3927 | ALZFORUM
In September 2023, VG-3927 became the first small-molecule TREM-2 agonist cleared to enter the clinic In October 2023, the first volunteer was treated in a Phase 1, placebo-controlled, single- and multiple-ascending-dose safety study being conducted in Miami
- Moving Target: New Biology Casts TREM2 as a Shifty Mark
Series - AD PD™ 2025: Advances in Science Therapy: Part 1 of 15: Finally, PET Tracers For α-Synuclein Yield Signal in Idiopathic Parkinson’s Part 2 of 15: New Partnership Forms to Harness AI for Alzheimer’s Research Part 3 of 15: Moving Target: New Biology Casts TREM2 as a Shifty Mark Part 4 of 15: TREM2: A Chill Pill for Neurons? Part 5 of 15: Trialists Grapple with How to Outsmart
- TREM2: A Chill Pill for Neurons? | ALZFORUM
TREM2 created quite the buzz at this year’s AD PD meeting, held April 1-5 in Vienna In the wake of a TREM2 agonist’s demise, scientists presented optimistic findings from early phase trials of a fresh batch of agonists Juxtaposing this were presentations that unveiled a new modus operandi for
- DNL919 - ALZFORUM
Background This TREM2 agonist antibody activates microglia to phagocytose amyloid DNL919 contains a transferrin-receptor binding sequence engineered into its Fc domain Thus, the antibody binds to the abundant transferrin receptors on endothelial cells of the blood-brain barrier, which facilitate its active transport into the brain
- All Roads Lead to TREM2: Gearing Up to Target This Receptor
Since the discovery of rare, yet potent risk variants in the TREM2 gene 11 years ago, the microglial receptor has emerged as a pivot point in the pathogenesis of Alzheimer’s disease Findings presented at the International Conference on Alzheimer’s and Parkinson’s Diseases, held March 28 to
- Ferried Into Brain, TREM2 Antibody Stirs Microglia | ALZFORUM
TREM2 antibody sports transferrin receptor binding domain to ease entry into brain It activated microglia and boosted brain glucose metabolism The antibody is in a first Phase 1 trial
|
|
|